- Home
- CVR vs BLRX Comparison
CVR vs BLRX Comparison
Compare CVR & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVR
- BLRX
- Stock Information
- Founded
- CVR 1920
- BLRX 2003
- Country
- CVR United States
- BLRX Israel
- Employees
- CVR N/A
- BLRX N/A
- Industry
- CVR Industrial Machinery/Components
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CVR Industrials
- BLRX Health Care
- Exchange
- CVR Nasdaq
- BLRX Nasdaq
- Market Cap
- CVR 14.9M
- BLRX 12.2M
- IPO Year
- CVR N/A
- BLRX 2011
- Fundamental
- Price
- CVR $10.80
- BLRX $2.71
- Analyst Decision
- CVR
- BLRX Buy
- Analyst Count
- CVR 0
- BLRX 2
- Target Price
- CVR N/A
- BLRX $26.00
- AVG Volume (30 Days)
- CVR 3.0K
- BLRX 26.6K
- Earning Date
- CVR 05-09-2025
- BLRX 05-27-2025
- Dividend Yield
- CVR 1.11%
- BLRX N/A
- EPS Growth
- CVR N/A
- BLRX N/A
- EPS
- CVR N/A
- BLRX N/A
- Revenue
- CVR $26,986,627.00
- BLRX $28,940,000.00
- Revenue This Year
- CVR N/A
- BLRX N/A
- Revenue Next Year
- CVR N/A
- BLRX N/A
- P/E Ratio
- CVR N/A
- BLRX N/A
- Revenue Growth
- CVR N/A
- BLRX 502.92
- 52 Week Low
- CVR $10.08
- BLRX $2.85
- 52 Week High
- CVR $22.27
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- CVR 29.33
- BLRX 35.52
- Support Level
- CVR $10.08
- BLRX $3.01
- Resistance Level
- CVR $14.14
- BLRX $3.61
- Average True Range (ATR)
- CVR 0.57
- BLRX 0.20
- MACD
- CVR -0.32
- BLRX 0.00
- Stochastic Oscillator
- CVR 12.83
- BLRX 0.00
About CVR Chicago Rivet & Machine Co.
Chicago Rivet & Machine Co is in the fastener industry in North America. The company operates in two segments namely fasteners and assembly equipment. Its fastener segment consists of the manufacture and sale of rivets, cold-formed fasteners, parts, and screw machine products. The assembly equipment segment consists mainly of the manufacture of automatic rivet setting machines, automatic assembly equipment, and parts and tools for such machines. The majority of revenue is from the fastener segment. Geographically, the majority is from the United States.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.